ID: ALA4089421

Max Phase: Preclinical

Molecular Formula: C17H20ClFN2O5S

Molecular Weight: 418.87

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOC2)c1O

Standard InChI:  InChI=1S/C17H20ClFN2O5S/c1-10-3-2-4-12(10)20-16(23)21-13-6-5-11(18)15(14(13)22)27(24,25)17(19)7-8-26-9-17/h3,5-6,12,22H,2,4,7-9H2,1H3,(H2,20,21,23)/t12-,17?/m1/s1

Standard InChI Key:  WHTWWZZWNMSJMC-MTATWXBHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 418.87

Molecular Weight (Monoisotopic): 418.0765

AlogP: 3.14

#Rotatable Bonds: 4

Polar Surface Area: 104.73

Molecular Species: ACID

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.31

CX Basic pKa:

CX LogP: 3.55

CX LogD: 1.82

Aromatic Rings: 1

Heavy Atoms: 27

QED Weighted: 0.51

Np Likeness Score: -0.68

References

1. Lu H, Yang T, Xu Z, Lin X, Ding Q, Zhang Y, Cai X, Dong K, Gong S, Zhang W, Patel M, Copley RCB, Xiang J, Guan X, Wren P, Ren F..  (2018)  Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.,  61  (6): [PMID:29406702] [10.1021/acs.jmedchem.7b01854]

Source

Source(1):

• Scientific Literature